ABMD:NAS (USA) Also trade in: Germany UK

Abiomed Inc

$ 260.93 4.37 (1.7%)
Volume: 764,913 Avg Vol (1m): 605,939
Market Cap $: 11.73 Bil Enterprise Value $: 11.27 Bil
P/E (TTM): 54.10 P/B: 13.78
Earnings Power Value 42.01
Net Current Asset Value 11.61
Tangible Book 17.82
Projected FCF 40.24
Median P/S Value 108.05
Graham Number 43.91
Peter Lynch Value 120.25
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 9/10

Current vs industry vs history
Cash-to-Debt No Debt
Equity-to-Asset 0.89
Interest Coverage No Debt
N/A
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 68.38
DISTRESS
GREY
SAFE
Beneish M-Score -2.33
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 59.9%
WACC 10.12%

Profitability & Growth : 8/10

Current vs industry vs history
Operating Margin % 28.09
Net Margin % 30.12
ROE % 30.07
ROA % 26.66
ROC (Joel Greenblatt) % 111.91
3-Year Total Revenue Growth Rate 37.10
3-Year Total EBITDA Growth Rate 74.90
3-Year EPS w/o NRI Growth Rate -2.60

» ABMD's 30-Y Financials

Financials (Next Earnings Date: 2019-05-02)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:ABMD

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Devices » Medical Devices    NAICS : 339112    SIC : 3841
Compare NYSE:TFX XSWX:SOON NYSE:VAR SZSE:300003 OCSE:WDH LSE:SN. XPAR:DIM ASX:COH NAS:ALGN LSE:CTEC NZSE:FPH NYSE:GMED OCSE:AMBU B NAS:IART OCSE:GN NAS:MASI OSTO:EKTA B NYSE:PEN NAS:LIVN SZSE:002223
Traded in other countries AIO.Germany 0H7S.UK
Address 22 Cherry Hill Drive, Danvers, MA, USA, 01923
Abiomed provides temporary mechanical circulatory support devices that are primarily used by interventional cardiologists and heart surgeons. The firm's products are primarily used for patients in need of hemodynamic support before, during, or after angioplasty and heart surgery procedures. They work by improving blood flow to coronary arteries or temporarily performing the pumping function of the heart. Abiomed receives the majority of revenue from its Impella product portfolio, which includes percutaneous micro heart pumps with integration motors and sensors and percutaneous catheter-based axial flow pumps. Abiomed generates the majority of its revenue in the United States.

Ratios

Current vs industry vs history
PE Ratio (TTM) 54.10
PE Ratio without NRI 54.10
Price-to-Owner-Earnings 79.01
PB Ratio 13.78
PS Ratio 16.32
Price-to-Free-Cash-Flow 62.86
Price-to-Operating-Cash-Flow 50.42
EV-to-EBIT 54.47
EV-to-EBITDA 51.27
EV-to-Revenue 15.31
PEG Ratio 0.83
Shiller PE Ratio 240.88
Current Ratio 6.76
Quick Ratio 5.99
Days Inventory 168.64
Days Sales Outstanding 43.70
Days Payable 76.55

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -2.40

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 14.60
Price-to-Projected-FCF 6.47
Price-to-Median-PS-Value 2.41
Price-to-Peter-Lynch-Fair-Value 2.16
Price-to-Graham-Number 5.93
Earnings Yield (Joel Greenblatt) % 1.83
Forward Rate of Return (Yacktman) % 20.76

More Statistics

Revenue (TTM) (Mil) $ 736.79
EPS (TTM) $ 4.81
Beta 1.26
Volatility % 48.64
52-Week Range $ 244.08 - 459.75
Shares Outstanding (Mil) 45.09

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N